

Quality Management System in INPI – BR: current status

Regional Workshop on Patent Examination Quality Management
Tokyo, June 27-29, 2018

Debora Shimba Carneiro
Daniel Marques Golodne


Historical Perspective

- 2002 First Examination Guidelines for Patents and Utility Models
First Examination Guidelines for Patents – Biotechnology and Pharmaceutical
- 2009 INPI as a **PCT** International Searching Authority and Preliminary Examining Authority
- 2013 Examination Guidelines for Patents – **Contents** of the Application
Examination Guidelines for **Utility** Models
- 2015 Examination Handbook for Patents and Utility Models (**procedures**)
Harmonized Examination Report Forms
Examination Guidelines for Patents – **Biotechnology**
- 2016 Examination Guidelines for Patents – **Patentability**
Examination Guidelines for Patents – **Software** Implemented
Checklist Verification – examination reports
- 2018 Examination Guidelines for Patents – **Chemistry**
Checklist: Data collection » Sampling Regimens

DIRPA – Technical Divisions

✓ 341 Patent Examiners

Grouped in 20 Technical Divisions



Current status – Quality Management System

- ❖ Started after becoming PCT authority (ISA/IPEA) – aug/2009
- ❖ Checklist of ISR/IPER
- ❖ Guidelines' revision
- ❖ Examination standard procedures (2015)
 - Search report
 - First action report
 - Second action report
 - Using third-parties subsidies
- ❖ Training on examination standard procedures and guidelines
- ❖ Checklist of examination reports

Search Form



SERVIÇO PÚBLICO FEDERAL
MINISTÉRIO DO DESENVOLVIMENTO, INDÚSTRIA E COMÉRCIO EXTERIOR
INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL

RELATÓRIO DE BUSCA

N.º do Pedido: PI0500941-3 **N.º de Depósito PCT:**
Data de Depósito: 23/03/2005
Prioridade Unionista: JP 85108/2004 (23/03/2004); JP 180122/2004 (17/06/2004)
Depositante: Central Research Institute Of Electric Power Industry (JP) , Kanai Office Corporation (JP)
Inventor: Kazuyoshi Ichikawa, Jun Inumaru, Kazuhiro Kidoguchi, Saburo Hara, Masami Ashizawa, Masao Kanai
Título: "Carbonização e gaseificação de biomassa e sistema de geração de energia "

1 - CLASSIFICAÇÃO INTERNACIONAL: IPC : C10J 3/46, C10J 3/68, C10B 47/10

2 - CAMPO DE BUSCA:

EPOQUE ESPACENET PATENTSCOPE
 DIALOG USPTO SINPI
 CAPES SITE DO INPI _____

3 - REFERÊNCIAS PATENTÁRIAS:

Número	Tipo	Data de publicação	Classificação principal	Relevância *
EP0921182	A1	06/06/99	C10J3/66	N,I
DE19730385	A1	21/01/99	C10J3/463	N,I
EP0563777	B1	29/05/96	C10J3/66	Y
JP2003326241	A	18/11/03	C10J3/00	A
JP2003253274	A	10/09/03	C10J3/00	A
US4478039	A	23/10/84	F02C3/28	A
EP1312662	A2	21/05/03	C10J3/66	A
WO9823898	A1	04/06/98	F23G5/30	A

4 - REFERÊNCIAS NÃO-PATENTÁRIAS:

Autor/Publicação	Data de publicação	Relevância *
Environmental Management, vol.39, Japan Environmental Management Association for Industry	2003	A



SERVIÇO PÚBLICO FEDERAL
 MINISTÉRIO DA INDÚSTRIA, COMÉRCIO EXTERIOR E SERVIÇOS
 INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL

Examination Form

RELATÓRIO DE EXAME TÉCNICO

N.º do Pedido: PI0401365-4 N.º de Depósito PCT:
 Data de Depósito: 04/03/2004
 Prioridade Unionista: -
 Depositante: Janio Batista Pereira (BRMG)
 Inventor: Janio Batista Pereira
 Título: "Carrinho de guia "

PARECER

Quadro 1 – Páginas do pedido examinadas			
Elemento	Páginas	n.º da Petição	Data
Relatório Descritivo			
Quadro Reivindicatório			
Desenhos			
Resumo			

Quadro 2 – Considerações referentes aos Artigos 10, 18, 22 e 32 da Lei n.º 9.279 de 14 de maio de 1996 – LPI		
Artigos da LPI	Sim	Não
A matéria enquadra-se no art. 10 da LPI (não se considera invenção)		
A matéria enquadra-se no art. 18 da LPI (não é patenteável)		
O pedido apresenta Unidade de Invenção (art. 22 da LPI)		
O pedido está de acordo com disposto no art. 32 da LPI		

Comentários/Justificativas

Quadro 3 – Considerações referentes aos Artigos 24 e 25 da LPI		
Artigos da LPI	Sim	Não
O relatório descritivo está de acordo com disposto no art. 24 da LPI		
O quadro reivindicatório está de acordo com disposto no art. 25 da LPI		

Comentários/Justificativas

Quadro 4 – Documentos citados no parecer		
Código	Documento	Data de publicação

Quadro 5 - Análise dos Requisitos de Patenteabilidade (Arts. 8.º, 11, 13 e 15 da LPI)		
Requisito de Patenteabilidade	Cumprimento	Reivindicações
Aplicação Industrial	Sim	
	Não	
Novidade	Sim	
	Não	
Atividade Inventiva	Sim	
	Não	

Comentários/Justificativas

Conclusão

O depositante deve responder a(s) exigência(s) formulada(s) neste parecer em até 90 (noventa) dias, a partir da data de publicação na RPI, de acordo com o Art. 36 da LPI.

Publique(m)-se a(s) exigência(s) técnica(s) (6.1)

Rio de Janeiro, 8 de junho de 2018.

Daniel Marques Golodne
 Chefe de Divisão/ Mat. Nº 1358388
 DIRPA / CGPAT II/DIMOL
 Deleg. Comp. - Port. INPI/PR Nº002/13

Productivity system: SISCAP



SISCAP - Sistema de Cadastramento da Produção
Conta: deborasc (DICIV)
DEBORA SHIMBA CARNEIRO



- Login ▾
- Novo ▾
- Produção ▾
- Estatística ▾
- Metas ▾
- Planilha ▾
- Busca ▾
- ISA/IPEA ▾
- IPC
- NPL ▾
- Filas
- Equipe
- Viagens a Serviço ▾
- Controle
- Gerenciamento ▾
- Diretriz Exame
- Logout

Início

Legenda N° do pedido Buscar

[Ver todas as notícias](#)

*O ingrediente mais importante na fórmula do sucesso é saber se relacionar bem com as pessoas, **Roosevelt***

[curtir](#) 11 pessoas curtiram isso



Pareceres da PROC cadastrados no último mês:

não há

Previsão da diciv iniciar o exame de 2007 é de julho de 2017
[Clique aqui para saber detalhes desta previsão](#)



















Pedidos de Primeiro Exame Prioritários ★

[BR102013010046](#)

[BR102015000949](#)

[BR102015001656](#)

Checklist
available after
publication of
reports

   	PI0618400-6 EP1954860 (B1)	CH	1º exame	Exigência (6.1)	Deslocar caracterizado por, Exigências Formais, Falta de Unidade de Invenção, Falta de Clareza das Reivindicações (Art. 25)	flaviapf(11/2016) ✓	 flaviapf	 VD	2397
   	PI0618623-8 EP1967625 (A1)	JP	2º exame	Exigência (6.1)	Deslocar caracterizado por, Falta de Clareza das Reivindicações (Art. 25)	flaviapf(11/2016) ✓	 flaviapf	 VD	2397
   	PI0619438-9 EP1969179 (A1)	OT	2º exame	Deferimento (9.1)	-	flaviapf(11/2016) ✓	 flaviapf	 VD	2395

Green =
conform

Red = at least
one non-
conformity

Checklist

Lista de Verificação - Qualidade

Legenda N° do pedido

Buscar

Examinador:	FLAVIA PINHEIRO FARIA	Pedido:	PI0618623
Revisor:	SIMONE CARVALHO RUFINO	Data Verificação:	08/03/2017
Tipo Despacho:	Exigência (6.1) - 2 etapa	Mês Parecer:	11/2016

Item	Atividade	Conformidade
1	Preenchimento do Relatório de Busca	
1.1	Foi utilizado o modelo de relatório de busca da Qualidade disponível no SISCAP?	<input type="radio"/> Sim <input type="radio"/> Não <input checked="" type="radio"/> Não se Aplica
1.2	Foram assinaladas as ferramentas de busca utilizadas?	<input type="radio"/> Sim <input type="radio"/> Não <input checked="" type="radio"/> Não se Aplica
1.3	O relatório de busca cita ao menos um documento?	<input type="radio"/> Sim <input type="radio"/> Não <input checked="" type="radio"/> Não se Aplica
1.4	Os documentos citados foram categorizados conforme a relevância (N, I, Y, A ou PN)	<input type="radio"/> Sim <input type="radio"/> Não <input checked="" type="radio"/> Não se Aplica
1.5	Os documentos citados como PN têm correspondente BR?	<input type="radio"/> Sim <input type="radio"/> Não <input checked="" type="radio"/> Não se Aplica
2	Preenchimento do Parecer Técnico	
2.1	Foi utilizado o modelo de parecer técnico da Qualidade disponível no SISCAP?	<input checked="" type="radio"/> Sim <input type="radio"/> Não <input type="radio"/> Não se Aplica
2.2	Caso exista petição de subsídio de terceiros, esta foi mencionada no parecer?	<input type="radio"/> Sim <input type="radio"/> Não <input checked="" type="radio"/> Não se Aplica
3	Preenchimento do Quadro referente à ANVISA, ao CGEN e às Sequências Biológicas	
3.1	Os comentários e justificativas referentes à ANVISA, ao CGEN, e às Sequências Biológicas foram inseridos logo após o respectivo quadro?	<input type="radio"/> Sim <input type="radio"/> Não <input checked="" type="radio"/> Não se Aplica
3.2	Caso o pedido se refira a Sequências Biológicas, foi preenchido o Quadro 1 com as páginas e/ou o código de controle?	<input type="radio"/> Sim <input type="radio"/> Não <input checked="" type="radio"/> Não se Aplica
4	Análise dos arts. 10/18/22/23/32 da LPI – Preenchimento do Quadro 2	
4.1	Tendo sido reportadas irregularidades com relação aos arts. 10/18/22/23/32 da LPI, foram elaborados comentários e justificativas a respeito?	<input type="radio"/> Sim <input type="radio"/> Não <input checked="" type="radio"/> Não se Aplica
4.2	Os comentários e justificativas referentes aos arts. 10/18/22/23/32 da LPI estão inseridos logo após o Quadro 2?	<input type="radio"/> Sim <input type="radio"/> Não <input checked="" type="radio"/> Não se Aplica
4.3	No caso de falta de unidade foram feitas as correlações entre os grupos de invenções e os números das reivindicações?	<input type="radio"/> Sim <input type="radio"/> Não <input checked="" type="radio"/> Não se Aplica
4.4	No caso de falta de unidade foi realizada busca e exame sobre a primeira invenção/matéria reivindicada?	<input type="radio"/> Sim <input type="radio"/> Não <input checked="" type="radio"/> Não se Aplica

1 – Filling in the search report

- 1.1 Was the search report template available in SISCAP used?
- 1.2 Were the boxes of the search tools used marked?
- 1.3 Does the search report cite at least one document?
- 1.4 Were the cited documents categorized according to the relevance (N, I, Y, A ou PN)?
- 1.5 Do the documents cited as PN have corresponding BR document?

2 – Filling in the technical opinion

- 2.2 In the event of an application for a third-party, was this mentioned in the report?

3 – Filling in the table concerning ANVISA, CGEN and Biological Sequence

- 3.1 Were the comments and justifications regarding ANVISA, CGEN, and the Biological Sequences inserted shortly after the respective table?
- 3.2 If the application refers to Biological Sequences, was Table 1 filled in with the pages and / or control code?

4 – Analysis of articles 10/18/22/23/32 of LPI – Filling in the table 2

- 4.1 In case of irregularities regarding articles 10/18/22/23/32, were the comments and justifications written?
- 4.2 Were the comments and justifications referring to articles 10/18/22/23/32 of the LPI inserted shortly after Table 2?
- 4.3 In case of lack of unity, were the correlations between the groups of inventions and the numbers of the claims made?
- 4.4 In case of lack of unity, was a search and examination carried out on the first invention / matter claimed?

5 – Analysis of articles 24/25 of LPI – Filling in the table 3

5.1 In case of irregularities regarding articles 24/25 of the LPI, were the comments and justifications written?

5.2 Were the comments and justifications referring to articles 24/25 of the LPI inserted shortly after Table 3?

6 – Filling in the table 4 - Documents cited in the opinion

6.1 Is the publication date of the cited documents (relevance N, I, Y or A) previous to the filing date (priority) of the application?

6.2 Are the cited documents (PN relevance) part of the prior art as determined in article 11 (§2 and §3) of the LPI?

6.3 Were all the prior art documents (considered as impeding the fulfillment of the patentability requirements) uploaded to SISCAP?

7 – Analysis of patentability requirements – Filling in the table 5

7.1 Were the "claims" column filled in with the analysed claims with respect to patentability requirements?

7.2 Is the marking of whether or not compliance with the patentability requirements in accordance with the comments and justifications?

7.3 Were the documents cited in table 4 used according to the relevance category presented in the search report?

7.4 Were the relevant parts of the documents used as prior art referenced (page number (s), column (s), etc.)?

7.5 Were the arguments relating to the patentability of all or part of the claimed subject matter inserted shortly after table 5?

8 – Conclusions of the report – Non-final Office action

8.1 Was the conclusion of the report based on article (s) of the LPI?

8.2 Has a non-final Office action been issued in cases where the application does not present a unit of invention / technical-functional unit or is not in accordance with article 32 of LPI?

9 – Conclusions of the report – Request of amendments

9.1 Was at least one technical request based on article (s) of the LPI?

10 – Conclusions of the report – Intention to grant

10.1 Were the application parts that will compose the granted patent document (table 1) correctly indicated (pages and petition number)?

10.2 If there was a change of title, was it updated in the heading of the report?

10.3 If there was a change in the title or name of the applicant, was it updated in the Sequence Listing?

10.4 Was the Sequence Listing in electronic format approved for the composition of the granted patent document marked as "B1" in SisBioList?

11 – Conclusions of the report – Final rejection

11.1 Was the conclusion of the report based on article (s) of the LPI?

11.2 Was the document used for rejection the same document used in the previous examination(s) report?

11.3 Was the article(s) used for the rejection the same used in the previous examination(s) report?


Checklist: data collection and preliminary analysis


Including only the examiners with full signatory authority (as of July, 2017)


Coordination/ Division	# Q.forms			% Q(red)	# examiners	# examiners w/ >=30 Q.forms	% progress Phase I (initial)	# non-conformities (by severity)			average non-conformity (by severity) (vs total Q's)			final sampling regimen count			
	GREEN	RED	total					1	2	3	1	2	3	reduced	normal	Additional	total
CGPAT I/DIFAR-I	300	75	375	20,0%	12	12	100,0%	62	24	15	16%	6%	4%	7	3	2	0
CGPAT I/DIFAR-II	255	60	315	19,0%	10	10	100,0%	31	27	15	10%	9%	5%	6	2	2	0
CGPAT I/DINOR	692	78	770	10,1%	7	7	100,0%	50	51	7	5%	5%	1%	6	1	0	0
CGPAT I/DIPOL	303	35	338	10,4%	8	8	100,0%	33	11	9	9%	3%	2%	7	0	1	0
CGPAT I/DITEX	288	73	361	20,2%	8	8	100,0%	59	34	11	15%	9%	3%	3	5	0	0
<i>(subtotal CGPAT I)</i>	<i>1838</i>	<i>321</i>	<i>2159</i>	<i>14,9%</i>	<i>45</i>	<i>45</i>	<i>100,0%</i>	<i>235</i>	<i>147</i>	<i>57</i>	<i>12%</i>	<i>6%</i>	<i>3%</i>	<i>29</i>	<i>11</i>	<i>5</i>	<i>0</i>
CGPAT II/DIALP	145	98	243	40,3%	8	8	100,0%	76	76	2	31%	31%	1%	3	0	2	3
CGPAT II/DIBIO	318	9	327	2,8%	8	8	100,0%	1	3	7	0%	1%	2%	6	2	0	0
CGPAT II/DIMOL	233	100	333	30,0%	11	11	100,0%	94	25	12	28%	7%	4%	5	4	1	1
CGPAT II/DIPAE	119	41	160	25,6%	5	5	100,0%	39	1	14	24%	1%	8%	3	0	1	1
CGPAT II/DIPAQ	163	18	181	9,9%	6	6	100,0%	6	16	0	3%	9%	0%	5	0	1	0
<i>(subtotal CGPAT II)</i>	<i>978</i>	<i>266</i>	<i>1244</i>	<i>21,4%</i>	<i>38</i>	<i>38</i>	<i>100,0%</i>	<i>216</i>	<i>121</i>	<i>35</i>	<i>18%</i>	<i>10%</i>	<i>3%</i>	<i>22</i>	<i>6</i>	<i>5</i>	<i>5</i>
CGPAT III/DICEL	588	4	592	0,7%	12	11	99,7%	0	4	0	0%	1%	0%	11	0	0	0
CGPAT III/DICIV	213	29	242	12,0%	7	7	100,0%	7	13	9	3%	5%	4%	4	3	0	0
CGPAT III/DIFEL	358	45	403	11,2%	12	12	100,0%	16	17	16	4%	4%	4%	7	3	2	0
CGPAT III/DIPEQ	381	76	457	16,6%	11	11	100,0%	48	31	9	12%	6%	2%	6	5	0	0
CGPAT III/DITEL	309	64	373	17,2%	12	12	100,0%	30	34	27	8%	9%	7%	5	4	2	1
<i>(subtotal CGPAT III)</i>	<i>1849</i>	<i>218</i>	<i>2067</i>	<i>10,5%</i>	<i>54</i>	<i>53</i>	<i>99,9%</i>	<i>101</i>	<i>99</i>	<i>61</i>	<i>5%</i>	<i>5%</i>	<i>3%</i>	<i>33</i>	<i>15</i>	<i>4</i>	<i>1</i>
CGPAT IV/DIMAT	51	49	100	49,0%	5	3	65,3%	46	29	12	30%	22%	10%	0	1	1	1
CGPAT IV/DIMEC	110	54	164	32,9%	7	5	78,1%	35	44	16	19%	24%	9%	1	0	3	1
CGPAT IV/DIMUT	611	102	713	14,3%	18	18	100,0%	93	29	36	14%	4%	5%	12	2	2	2
CGPAT IV/DINEC	412	20	432	4,6%	9	8	88,9%	11	5	7	4%	1%	2%	6	2	0	0
CGPAT IV/DITEM	33	27	60	45,0%	2	2	100,0%	8	13	9	13%	22%	15%	0	0	2	0
<i>(subtotal CGPAT IV)</i>	<i>1217</i>	<i>252</i>	<i>1469</i>	<i>17,2%</i>	<i>41</i>	<i>36</i>	<i>89,6%</i>	<i>193</i>	<i>120</i>	<i>80</i>	<i>15%</i>	<i>10%</i>	<i>6%</i>	<i>19</i>	<i>5</i>	<i>8</i>	<i>4</i>
total (DIRPA)	5882	1057	6939	15,2%	178	172	97,6%	745	487	233	12%	8%	4%	103	37	22	10


Severity	Sampling regimen applicable			
	<i>Reduced</i>	<i>Normal</i>	<i>Additional</i>	<i>Total</i>
1	0 to 25%	25,1 to 50%	50,1 to 75%	>75%
2	0 to 10%	10,1 to 20%	20,1 to 40%	>40%
3	0 to 5%	5,1 to 10%	10,1 to 20%	>20%



Average productivity (per month)	Sample size (per regimen)		
2 to 8	2	2	3
9 to 15	2	3	5
16 to 25	3	5	8











Q. form item	Activity	severity	CGPAT I					CGPAT II				CGPAT III				CGPAT IV				Total			
			DIFAR-I	DIFAR-II	DINOR	DIPOL	DITEX	DIALP	DIBIO	DIMOL	DIPAE	DIPAQ	DICEL	DICIV	DIFEL	DIPEQ	DITEL	DIMAT	DIMEC		DIMUT	DINEC	DITEM
1.1	Search report template available in SISCAP used?	1	1																2			3	
1.2	Boxes of the search tools used marked?	1	2	1	3	2	3	1		4				1	1	2	1	2	13	2		38	
1.3	Search report cites at least one document?	1	2			3				1						2			3			11	
1.4	Cited documents categorized (N, I, Y, A or PN)?	1	3	2	1	2	1			8		2		1	1	9	6	1	1	5		43	
1.5	PN-type docs have corresponding BR document?	2	1																			1	
2.1	Was the technical report model available in SISCAP used?	1		2		1										1		2				6	
2.2	Third-party submission: was this mentioned in the report?	2					2	1												1		4	
3.1	Comments - ANVISA, CGEN & Biol.Sequences: proper position?	1						1			3											4	
3.2	Biological Sequences: Table 1 filled in with the pages etc?	1																				0	
4.1	Articles 10/18/22/23/32: are there comments?	2				1	1			1					4	1			1			9	
4.2	Articles 10/18/22/23/32: comments inserted after Table 2?	1	1	3	1	1	2	4		12				1		2	2	1	2			32	
4.3	Lack of unity: correlations between groups and claims?	2			1				3	1							6		1			12	
4.4	Lack of unity: search and examination on the first invention?	2			1	1				2						1	3		1			9	
5.1	Articles 24/25: are there comments?	2	1	2	1	2	6	1				1	1		11				4		2	33	
5.2	Articles 24/25: comments inserted after Table 3?	1		2	9	8	15	5		24	15	1		1	3	6	9		36			134	
6.1	Cited documents: published prior to the filing/priority date?	2	1		3	1		2				6	1	1		2	1		1			19	
6.2	PN-type docs are in agreement with article 11 (§2 and §3)?	2										1		1								2	
6.3	Prior art docs uploaded to SISCAP?	2	7	17	23		14	52		7	1	2	2	4	7	6	2	7	19	8		178	
7.1	Analysed claims: proper filling of the form?	1	4	4	10	3	1	7	1	6		1		1		4	3	1	14	2	3	66	
7.2	Patentability comments: relate with the marking of compliance?	2	5	1	17	5	5	15	1	5		6		3	5	13	11	10	25	6	3	1	137
7.3	Cited documents: used according to the relevance (search)?	1	11	4	14	2	7	28		9	1	1		2	9	24	7	3		4	2	128	
7.4	Cited documents: relevant parts are indicated (pages etc)?	1	38	13	10	7	30	27		30	17	1		3	3	10		23	2	13	5	4	236
7.5	Patentability: comments inserted shortly after table 5?	1			2	4		3			3					2	2	26	1		1	44	
8.1	Was the conclusion of the report based on article (s) of the LPI?	3			1	1	3				2			4		10	10		4			35	
8.2	Non-final Office action: unit of invention / article 32 of LPI?	2		3		1	1	1		1						1	1		2	1		12	
9.1	At least one technical request based on article (s) of the LPI?	3	1	4	1	2	6				12			2	9	1	7		16	19	4	2	86
10.1	Granting: all parts correctly indicated?	3	14	9	3	6	2	1	5	6				7	2	8	9	2		7	3	7	91
10.2	Title: updated in the heading of the report?	2	9	4	5		5	1	2	6			1	3	4	12	2			4	1	10	69
10.3	Sequence listing: updated title or name of the applicant?	2								2												2	
10.4	Sequence listing in electronic format: assigned as "B1" [grant]?	3							2	6												8	
11.1	Conclusion of the report based on article (s) of the LPI?	3																				0	
11.2	Document for rejection is the same previously used?	3			1			1								1				4		7	
11.3	Article(s) for rejection are the same used previously?	3		2	1										1					2		6	

Intention to grant

Q.form item	severity	CGPAT I					CGPAT II					CGPAT III					CGPAT IV				
		DIFAR-I	DIFAR-II	DINOR	DIPOL	DITEX	DIALP	DIBIO	DIMOL	DIPAE	DIPAQ	DICEL	DICIV	DIFEL	DIPEQ	DITEL	DIMAT	DIMEC	DIMUT	DINEC	DITEM
1.1	1																				
1.2	1			1												2					
1.3	1																1				
1.4	1		1													1	1				
1.5	2																				
2.1	1		2		1									1							
2.2	2																1				
3.1	1																		3		
3.2	1																				
4.1	2				1																
4.2	1				1																
4.3	2																				
4.4	2																				
5.1	2														3					1	
5.2	1													1	2						
6.1	2			1																	
6.2	2																				
6.3	2		2												1						
7.1	1																			2	
7.2	2														1	18		1			
7.3	1	1				1								1							
7.4	1	1																			
7.5	1				3											18					
8.1	3																				
8.2	2																				
9.1	3																				
10.1	3	14	9	3	6	2	1	5	6				7	2	8	9	2		7	3	7
10.2	2	9	4	5		5	1	2	6			1	3	4	12	2			4	1	10
10.3	2								2												
10.4	3						2	6													
11.1	3																				
11.2	3																				
11.3	3																				

Final rejection

Q.form item	severity	CGPAT I					CGPAT II					CGPAT III					CGPAT IV				
		DIFAR-I	DIFAR-II	DINOR	DIPOL	DITEX	DIALP	DIBIO	DIMOL	DIPAE	DIPAQ	DICEL	DICIV	DIFEL	DIPEQ	DITEL	DIMAT	DIMEC	DIMUT	DINEC	DITEM
1.1	1																				
1.2	1																				1
1.3	1																				
1.4	1																				
1.5	2																				
2.1	1																				1
2.2	2																				
3.1	1																				
3.2	1																				
4.1	2														1						
4.2	1														2		2		1		1
4.3	2																				
4.4	2																				
5.1	2	1																			1
5.2	1																				1
6.1	2																				
6.2	2																				
6.3	2																				
7.1	1																				
7.2	2																				
7.3	1																				
7.4	1	6	2	2	1	7	5														
7.5	1																				
8.1	3																				
8.2	2																				
9.1	3																				
10.1	3																				
10.2	2																				
10.3	2																				
10.4	3																				
11.1	3																				
11.2	3																				
11.3	3																				

Examiner	Division	# Q.forms				average non-conformity (by severity) (vs total Q's)			sampling regimen:	average productivity (12 last months)	sample size (per month)
		GREEN	RED	total	% Q(red)	1	2	3			
Examiner 1	di...	30	8	38	21%	5%	11%	5%	NORMAL	9,7	3
Examiner 2	di...	33	0	33	0%	0%	0%	0%	REDUCED	6,6	2
Examiner 3	di...	30	3	33	9%	0%	6%	3%	REDUCED	11,0	2
Examiner 4	di...	29	6	35	17%	6%	3%	9%	NORMAL	9,8	3
Examiner 5	di...	32	7	39	18%	3%	13%	3%	NORMAL	11,6	3
Examiner 6	di...	29	2	31	6%	3%	0%	3%	REDUCED	8,8	2
Examiner 7	di...	30	3	33	9%	3%	3%	3%	REDUCED	10,2	2
Examiner 8	di...	25	5	30	17%	10%	7%	3%	REDUCED	8,3	2

# non conformities	severity	Item	Activity
0	1	1.1	Was the search report template available in SISCAP used?
0	1	1.2	Were the boxes of the search tools used marked?
0	1	1.3	Does the search report cite at least one document?
1	1	1.4	Were the cited documents categorized according to the relevance (N, I, Y, A ou PN)?
0	2	1.5	Do the documents cited as PN have corresponding BR document?
0	1	2.1	Was the technical report model available in SISCAP used?
0	2	2.2	In the event of an application for a third-party, was this mentioned in the report?
0	1	3.1	Were the comments and justifications regarding ANVISA, CGEN, and the Biological Sequences inserted shortly after the respective table?
0	1	3.2	If the application refers to Biological Sequences, was Table 1 filled in with the pages and / or control code?
0	2	4.1	In case of irregularities regarding articles 10/18/22/23/32, were the comments and justifications written?
0	1	4.2	Were the comments and justifications referring to articles 10/18/22/23/32 of the LPI inserted shortly after Table 2?
0	2	4.3	In case of lack of unity, were the correlations between the groups of inventions and the numbers of the claims made?
0	2	4.4	In case of lack of unity, was a search and examination carried out on the first invention / matter claimed?
1	2	5.1	In case of irregularities regarding articles 24/25 of the LPI, were the comments and justifications written?
0	1	5.2	Were the comments and justifications referring to articles 24/25 of the LPI inserted shortly after Table 3?
1	2	6.1	Is the publication date of the cited documents (relevance N, I, Y or A) previous to the filing date (priority) of the application?
1	2	6.2	Are the cited documents (PN relevance) part of the prior art as determined in article 11 (§2 and §3) of the LPI?
5	2	6.3	Were all the prior art documents (considered as impeding the fulfillment of the patentability requirements) uploaded to SISCAP?
1	1	7.1	Were the "claims" column filled in with the analysed claims with respect to patentability requirements?
4	2	7.2	Is the marking of whether or not compliance with the patentability requirements in accordance with the comments and justifications?
4	1	7.3	Were the documents cited in table 4 used according to the relevance category presented in the search report?
4	1	7.4	Were the relevant parts of the documents used as prior art referenced (page number (s), column (s), etc.)?
0	1	7.5	Were the arguments relating to the patentability of all or part of the claimed subject matter inserted shortly after table 5?
0	3	8.1	Was the conclusion of the report based on article (s) of the LPI?
0	2	8.2	Has a non-final Office action been issued in cases where the application does not present a unit of invention / technical-functional unit or is not in accordance with article 32 of LPI?
3	3	9.1	Was at least one technical request based on article (s) of the LPI?
7	3	10.1	Were the application parts that will compose the granted patent document (table 1) correctly indicated (pages and petition number)?
3	2	10.2	If there was a change of title, was it updated in the heading of the report?
0	2	10.3	If there was a change in the title or name of the applicant, was it updated in the Sequence Listing?
0	3	10.4	Was the Sequence Listing in electronic format approved for the composition of the granted patent document marked as "B1" in SisBioList?
0	3	11.1	Was the conclusion of the report based on article (s) of the LPI?
0	3	11.2	Was the document used for rejection the same document used in the previous examination(s) report?
0	3	11.3	Was the article(s) used for the rejection the same used in the previous examination(s) report?

Thank you !!
ありがとうございます

INPI INSTITUTO
NACIONAL DA
PROPRIEDADE
INDUSTRIAL

deborasc@inpi.gov.br
golodne@inpi.gov.br